SEC Form 4 · accession 0001209191-17-003704
Oncotelic Therapeutics, Inc. · OTLC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William D Schwieterman
Officer — President and CEO · Director
Period of report
Jan 12, 2017
Accepted (ET)
Jan 13, 2017 · 5:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000908259
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1,F2 | $0.375 | Jan 12, 2017 | A | 550,000 | A | — | Jan 12, 2027 | Common Stock | 550,000 | 550,000 | D |
Explanation of responses
- F1Dr. Schwieterman was awarded options to purchase Mateon Therapeutics, Inc. common stock, $0.01 par value per share, pursuant to the Mateon Therapeutics, Inc. 2017 Equity Incentive Plan in connection with his service as President and Chief Executive Officer.
- F2The Options will vest in forty-eight equal monthly installments beginning one month after the grant date.